A Single Ascending Dose of HRS-2162 in Healthy Subjects

Recruiting Phase 1 Interventional Study
Reversal of Neuromuscular Blockade
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 45
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
64 (estimated)
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. The subjects voluntarily signed the informed consent form. 2. Applicants must be between 18 and 45 years old at the time of signing the informed consent form, and both men and women are eligible . 3. ASA classification is Grade I (only Parts Two and three) 4. Male weight ≥50 …
Contacts

Yuanyuan Huang

0518-82342973

yuanyuan.huang@hengrui.com

CONTACT